Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting
Studies measured postural stability after middle-of-the-night awakening and next morning compared to zolpidem ER, as well as next-morning driving performance




TOKYO and STAMFORD, Conn., June 5, 2018 /PRNewswire/ -- Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today presented the results of two key Phase 1 clinical studies of their investigational sleep/wake regulation agent lemborexant at the 32nd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2018), June 2-6, Baltimore, MD. Lemborexant is currently being studied for the potential treatment of multiple sleep disorders. Positive topline results from these Phase 1 studies as well as a Phase 3 study (SUNRISE 1), which compared lemborexant to placebo in patients with a sleep disorder and included the first-ever head-to-head superiority comparison versus zolpidem extended release (zolpidem ER) as a secondary endpoint, were previously announced.

Phase 1 Study 108 – "Auditory Awakening Threshold to Evaluate Ability to Awaken After Administration of Lemborexant Versus Zolpidem" (Poster # 097) met its primary endpoint resulting in a statistically significant difference in postural stability with both doses of lemborexant compared to zolpidem ER in the middle of the night. The mean changes from baseline in body sway, a measure of postural stability, were -1.1 units for placebo, 5.8 units for lemborexant 5 mg, 8.1 units for lemborexant 10 mg, and 20.4 units for zolpidem ER 6.25 mg; (p<0.0001 vs. zolpidem ER for both lemborexant 5 mg and 10 mg).

Healthy volunteers 55 years and older (n=56) were administered treatments at bedtime, and body sway was assessed upon awakening participants after approximately four hours in bed. A 7 unit increase from baseline was defined as a clinically meaningful increase in body sway, as benchmarked to the effect of alcohol on the same measure of postural stability. Zolpidem ER increased body sway at a magnitude almost three times greater than the increase in body sway associated with a blood alcohol content (BAC 0.05 percent1) near the legal driving limit. Lemborexant 5 mg did not result in a clinically meaningful increase in body sway, while lemborexant 10 mg increased body sway to just above the clinically meaningful threshold.

The next morning, shortly after the end of eight hours in bed, unlike zolpidem ER, neither dose of lemborexant had statistically significant residual effects on this measure of postural stability as compared to placebo. The mean changes from baseline in body sway were -2.2 units for placebo, 0.4 units for lemborexant 5 mg, -0.4 units for lemborexant 10 mg, and 5.0 units for zolpidem ER 6.25 mg (p=NS [not significant] for both doses of lemborexant vs. placebo, p=0.01 for zolpidem ER vs. placebo).

"Postural instability is thought to be the single best predictor of falls. Significant unmet need exists for a treatment that can help people awaken in the night or the next morning without this type of impairment," said Lynn Kramer, MD, Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai. "If approved, lemborexant, our investigational sleep/wake regulation agent, may have the potential to reduce the risk of postural instability."

In this Phase 1 study, there were no serious adverse events (AE). Headache was the only AE observed in two or more subjects taking lemborexant. The only AE that occurred in more than one subject in any treatment period was nasopharyngitis, which occurred in the placebo treatment period. Rates of treatment-emergent AEs were low and of mild or moderate severity. Two subjects discontinued due to an AE. There were no AEs of somnolence.

A secondary study objective was to evaluate the effects of lemborexant 5 mg and 10 mg on the auditory awakening threshold (AAT), a measure of the ability to be awakened by an external stimulus at approximately four hours post-dose, compared to zolpidem ER and placebo. A clinically meaningful increase in AAT was pre-specified as an 8-decibel (dB) change from baseline.

Neither dose of lemborexant had a statistically significant difference relative to placebo or zolpidem ER on the ability to awaken to an external stimulus. The mean treatment differences compared to placebo were 1.7 dB for lemborexant 5 mg, -0.9 dB for lemborexant 10 mg, and 7.2 dB for zolpidem ER 6.25 mg (p=NS). Of the subjects who completed all four treatments, eight subjects taking zolpidem ER did not awaken to the loudest tone of 105 dB, compared with four subjects in each of the other treatment groups (placebo, n=42; lemborexant 5 mg, n=47; lemborexant 10 mg, n=50; and zolpidem ER, n=50). Varying n's were due to either the subject already being awake thus no AAT was administered, or a technical issue with the AAT equipment.

"By acting on the orexin neurotransmitter system, which regulates wakefulness, lemborexant appears to affect sleep and wake by dampening excessive wakefulness and does not appear to impede the ability to awaken to external stimuli," said Russell Rosenberg, PhD, D. ABSM, a Principal Investigator in lemborexant studies and former Chairman of the Board of the National Sleep Foundation. "As the largest study conducted to date evaluating postural stability and auditory awakening threshold in the middle of the night, these data about the effects of lemborexant on measures of balance and responsiveness to external stimuli are encouraging with respect to addressing current unmet needs in the treatment of sleep disorders."

In addition, return to sleep latency was evaluated as an exploratory endpoint and both doses of lemborexant had faster return to sleep after being awakened in the middle of the night compared to placebo. The mean treatment differences compared to placebo were -22.5 minutes for lemborexant 5 mg, -28.7 minutes for lemborexant 10 mg, and -21.0 minutes for zolpidem ER (p<0.0001 for all treatment groups compared to placebo). Lemborexant 10 mg also facilitated the return to sleep faster than zolpidem ER 6.25 mg (p=0.02).

These results support findings from SUNRISE 1, a recently completed Phase 3 study of lemborexant (5 mg and 10 mg) versus placebo, including a superiority comparison to zolpidem ER as a secondary endpoint. The study met endpoints of time to sleep onset and sleep maintenance as measured by polysomnography, as well as body sway upon awakening, when compared to placebo and zolpidem ER. In this study, lemborexant had rates of discontinuation due to AEs comparable to placebo, with the most common AEs in the lemborexant arms being headache and somnolence. 

Phase 1 Study 106 – "Results From an On-Road Driving Performance Study in Non-elderly and Elderly Healthy Subjects with Dual Orexin Receptor Antagonist Lemborexant" (Poster # 099) evaluated next-morning effects of lemborexant compared with placebo, with zopiclone included as a positive control, by measuring adult and elderly participants' (n=48) driving performance via an on-road driving test. The primary endpoint was to evaluate difference from placebo of standard deviation of lateral position (SDLP), an index of weaving, during an on-road driving test on the mornings following the first and last dose of drug in each treatment period. Drug-placebo differences in SDLP >2.4 cm are considered to reflect clinically meaningful driving impairment, as benchmarked against a BAC of 0.05 percent.

Lemborexant 2.5, 5 and 10 mg showed no statistically significant impairment of driving performance, as measured by mean changes in SDLP, after either single (Day 2) or multiple (Day 9) dose administration compared to placebo, meeting the study's primary endpoint. In contrast, zopiclone 7.5 mg significantly increased mean SDLP as compared to placebo. The mean drug-placebo changes in SDLP (in centimeters) compared to placebo for Day 2 were 0.02 cm for lemborexant 2.5 mg, 0.23 cm for lemborexant 5 mg, 0.73 cm for lemborexant 10 mg, and 2.04 cm for zopiclone 7.5 mg. For Day 9, the mean drug-placebo changes in SDLP were 0.48 cm for lemborexant 2.5 mg, 0.36 cm for lemborexant 5 mg, 0.74 cm for lemborexant 10 mg, and 1.88 cm for zopiclone 7.5 mg. The upper bound of the 95 percent confidence intervals for the mean changes in SDLP were all below 2.4 cm for all three doses of lemborexant on Days 2 and 9, indicating that there was not clinically meaningful driving impairment. The upper bound of the 95 percent confidence intervals for the mean changes in SDLP for zopiclone was greater than 2.4 cm on Days 2 and 9, demonstrating assay sensitivity.  

No drives were stopped before completion in the lemborexant treatment groups, whereas, three drives out of a total of 384 (0.8 percent) were terminated before scheduled completion, all after the use of zopiclone. No serious or severe AEs were reported in any treatment group. There were no treatment-related AEs leading to withdrawal from the study. The most common AEs observed in the lemborexant treatment groups were somnolence, headache, and dry mouth. Somnolence was reported more frequently with lemborexant 10 mg than lemborexant 2.5 mg and 5 mg. 

"Sleep medications should not only improve the ability to sleep through the night, but also allow patients to awaken in the middle of the night, if needed, and to function upon awakening," said Marcelo Bigal, MD, PhD, Chief Medical Officer, Purdue Pharma. "We are pleased to share these study results and are committed to exploring the value of lemborexant in specific unmet needs of patients with sleep disorders."

Discovered by Eisai, lemborexant is being jointly developed by Eisai and Purdue Pharma. Information about ongoing clinical studies is available at clinicaltrials.gov

This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.

<Notes to editors>

  1. About Lemborexant
    Lemborexant, an investigational dual orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule compound which inhibits orexin neurotransmission by binding competitively to two subtypes of orexin receptors (orexin receptor 1 and 2). In individuals with sleep/wake disorders, it is possible that the orexin system which regulates sleep and wakefulness is not functioning normally. During normal periods of sleep, orexin system activity is suppressed, suggesting it is possible to purposefully counteract inappropriate wakefulness and facilitate the initiation and maintenance of sleep by interfering with orexin neurotransmission. Therefore, Eisai and Purdue Pharma have been developing lemborexant as a potential treatment for multiple sleep disorders.

    A Phase 2 clinical study of lemborexant in patients with irregular sleep-wake rhythm disorder (ISWRD) and mild to moderate Alzheimer's dementia is underway. Lemborexant is the only sleep/wake agent being studied for ISWRD.
  2. About Study 108
    A randomized, double-blind, four-period, Phase 1 crossover study evaluated the effect of lemborexant on postural stability, auditory awakening threshold and cognitive performance in healthy volunteers age 55 years and older; 120 subjects were screened, 63 randomized, and 56 completed all four treatment groups. Participants were administered a single dose of placebo, lemborexant 5 mg, lemborexant 10 mg, or zolpidem ER 6.25 mg, and had eight-hour polysomnograms at baseline and at each single-dose treatment. If not already awake, subjects were awakened, preferentially from stage non-REM 2 in the middle of the night (between four and four and a half hours post-bedtime/post-dose). At bedside, body sway with eyes closed was measured in units of 1/3o angle of arc for 60 seconds using an ataxiameter device. Increases from baseline of greater than or equal to 7 units were pre-specified as clinically meaningful, benchmarked to effect of alcohol at 0.5g/kg. At eight hours post-dose, body sway was assessed in the same manner.

    The study also evaluated the effects of lemborexant on the AAT. Subjects slept with insert earphones, an auditory stimulus apparatus that produced 1000Hz tones for three seconds at 15-second intervals. The starting dB level was 15, increasing five dB to a maximum of 105dB, until the subject stated, "I'm awake." The awakening threshold was the dB level one level below the response.
  3. About Study 106 
    A randomized, double-blind, placebo- and active-controlled, four-period, Phase 1 crossover study evaluated the effect of lemborexant in 48 healthy adult and elderly volunteers to evaluate on-road driving performance. Participants (n=24 elderly and n=24 non-elderly) were treated at bedtime with two out of three dose levels of lemborexant (2.5, 5 or 10 mg) and placebo for eight consecutive days, and zopiclone 7.5 mg as an active control on days one and eight only, with placebo given for the six days in between. Standardized one-hour on-road driving tests on the second and ninth days were started approximately nine hours post-dose.
  4. About Sleep Disorders
    Population studies show that sleep disorders affect many more people worldwide than previously thought. Insomnia disorder is characterized by difficulty falling sleep, staying asleep or both, despite an adequate opportunity to sleep, that can lead to daytime consequences such as fatigue, difficulty concentrating and irritability. Insomnia disorder is the most common sleep disorder, with persistent insomnia symptoms experienced by approximately 10 percent of the adult population.

    Sleeping well is essential for good health, including brain health. Poor sleep is associated with a wide range of health consequences, including an increased risk of hypertension, accidental injury, diabetes, obesity, depression, heart attack, stroke and dementia, as well as adverse effects on mood and behavior.

    Experimental studies in animals and humans provide evidence of associations between sleep and disease risk factors, diseases and mortality. Studies suggest an optimal sleep duration between seven and eight hours. Women are 1.4 times more likely than men to suffer from insomnia.

    Older adults also have higher prevalence of insomnia; aging is often accompanied by changes in sleep patterns, including disrupted sleep, frequent waking and early waking, that can lead to less sleep time.
  5. About Eisai Inc.
    At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

    Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities.

    Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
  6. About Purdue Pharma L.P.
    Purdue Pharma L.P. is a privately-held pharmaceutical company headquartered in Stamford, Conn. Purdue Pharma is part of a network of independent associated companies dedicated to providing patients and providers with innovative medicines. The company's leadership and employees are committed to serving healthcare professionals, patients and caregivers by providing quality products and educational resources that make a positive impact on healthcare — and on lives. For more information, please visit www.purduepharma.com.




Eisai Inc.

Purdue Pharma L.P.

Michele Randazzo

Danielle Lewis







SOURCE Eisai Co., Ltd.

Type Press Release

Date Released June 05, 2018

May 9, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...

Apr 26, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody...

Apr 7, 2022

Eisai stands with people living with Alzheimer’s disease (AD), health care professionals and other members of our AD community. We respect that the Centers for Medicare and Medicaid Services...

Alerts - Release page
* Required Fields